<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="2913">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 08, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04463602</url>
  </required_header>
  <id_info>
    <org_study_id>DESI.20.004</org_study_id>
    <nct_id>NCT04463602</nct_id>
  </id_info>
  <brief_title>Desidustat in the Management of COVID-19 Patients</brief_title>
  <official_title>A Phase 2b, Multicenter, Open-label, Randomized, Comparator-Controlled, Study to Evaluate the Efficacy and Safety of Desidustat Tablet for the Management of COVID-19 Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cadila Healthcare Limited</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cadila Healthcare Limited</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is a Phase 2b, Multicenter, Open-label, Randomized, Comparator- Controlled Study&#xD;
      to Evaluate the Efficacy and Safety of Desidustat Tablet for the Management of mild, moderate&#xD;
      and severe COVID-19 patients. 100 mg of Desidustat will be administered for a period of 14&#xD;
      days along with recommended standard care during the trial.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a phase 2b, multicenter, open-label, randomized, comparator-controlled clinical trial&#xD;
      to evaluate the efficacy and safety of Desidustat for the management of COVID-19 patients.&#xD;
      First 12 mild to moderate subjects (Test arm: Desidustat + Standard of care arm, 06 subjects&#xD;
      and Reference arm: Standard of care, 06 subjects) will be enrolled in the study and after&#xD;
      evaluation of safety of these 12 subjects by Data Monitoring Committee other 12 severe&#xD;
      subjects (Test arm: Desidustat + Standard of care arm, 06 subjects and Reference arm:&#xD;
      Standard of care arm, 06 subjects) will be enrolled in the study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">July 25, 2020</start_date>
  <completion_date type="Anticipated">February 28, 2021</completion_date>
  <primary_completion_date type="Anticipated">January 25, 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Clinical status of subject on a 7-point ordinal scale</measure>
    <time_frame>Week 2</time_frame>
    <description>Not hospitalized, no limitations on activities.&#xD;
Not hospitalized, limitation on activities.&#xD;
Hospitalized, not requiring supplemental oxygen.&#xD;
Hospitalized, requiring supplemental oxygen.&#xD;
Hospitalized, on non-invasive ventilation or high flow oxygen devices.&#xD;
Hospitalized, on invasive mechanical ventilation or extracorporeal membrane oxygenation (ECMO).&#xD;
Death.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>PCR test</measure>
    <time_frame>Week 2 and Week 4</time_frame>
    <description>PCR for SARS-CoV-2 in pharyngeal swab</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Supplemental Oxygen</measure>
    <time_frame>Week 2 and Week 4</time_frame>
    <description>Occurrence of supplemental Oxygen</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mechanical Ventilation</measure>
    <time_frame>Week 2 and Week 4</time_frame>
    <description>Occurrence of Mechanical Ventilation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Treatment-Emergent Adverse Events</measure>
    <time_frame>Week 2 and Week 4</time_frame>
    <description>Occurence of Adverse events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Laboratory Assessments</measure>
    <time_frame>Week 2 and Week 4</time_frame>
    <description>Laboratory Assessments</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>C-reactive protein (CRP)</measure>
    <time_frame>Week 2 and Week 4</time_frame>
    <description>Inflammatory Biomarker</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Interleukin 6 (IL-6)</measure>
    <time_frame>Week 2 and Week 4</time_frame>
    <description>Inflammatory Biomarker</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>D-dimer</measure>
    <time_frame>Week 2 and Week 4</time_frame>
    <description>Inflammatory Biomarker</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>COVID-19</condition>
  <arm_group>
    <arm_group_label>Desidustat + Standard of Care</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Test: Desidustat + Standard of care&#xD;
Desidustat 100 mg for the duration of 14 days along with the recommended standard of care at the time of conduct of trial.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard of Care</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Control: Standard of care&#xD;
Standard of care treatment for the duration of 14 days at the time of conduct of trial.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Desidustat</intervention_name>
    <description>100 mg once daily</description>
    <arm_group_label>Desidustat + Standard of Care</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Standard of Care</intervention_name>
    <description>Standard of care as per local authority</description>
    <arm_group_label>Desidustat + Standard of Care</arm_group_label>
    <arm_group_label>Standard of Care</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Ability to comprehend and willingness to sign a written ICF by the subject/impartial&#xD;
             witness.&#xD;
&#xD;
          2. Male and Females, age â‰¥18 years at enrollment.&#xD;
&#xD;
          3. Understands and agrees to comply with planned study procedures.&#xD;
&#xD;
          4. Agrees to the collection of pharyngeal swabs and blood sample as per protocol.&#xD;
&#xD;
          5. Has laboratory-confirmed SARS-CoV-2 infection as determined by PCR, or other&#xD;
             commercial or public health assay in any specimen within one week.&#xD;
&#xD;
          6. Illness of any duration, and at least one of the following:&#xD;
&#xD;
               1. Radiographic infiltrates by imaging (chest x-ray)&#xD;
&#xD;
               2. Clinical assessment (evidence of rales/crackles or other clinical symptoms on&#xD;
                  exam).&#xD;
&#xD;
          7. Women of childbearing potential must agree to use at least one primary form of&#xD;
             contraception for the duration of the study (acceptable methods will be determined by&#xD;
             the site).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. ALT/AST &gt;5 times the upper limit of normal.&#xD;
&#xD;
          2. Stage V CKD (i.e. eGFR &lt;15 ml/min/1.73 m2 or requiring dialysis).&#xD;
&#xD;
          3. Pregnant or breast feeding.&#xD;
&#xD;
          4. Severe co-morbidity (e.g. uncontrolled hypertension and uncontrolled DM, systemic&#xD;
             disease which affect the vital organs severity, immunocompromised patients etc.) as&#xD;
             per investigator's assessment.&#xD;
&#xD;
          5. Comorbid condition like myocardial infarction or heart failure within 90 days of&#xD;
             recruitment.&#xD;
&#xD;
          6. Prolong QT interval (&gt;450 ms).&#xD;
&#xD;
          7. Patients on invasive mechanical ventilation.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <gender_based>Yes</gender_based>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dr Deven Parmar, MD</last_name>
    <role>Study Director</role>
    <affiliation>Cadila Healthcare Ltd.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Avant Sante Site 1</name>
      <address>
        <city>Monterrey</city>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Mexico</country>
  </location_countries>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>July 7, 2020</study_first_submitted>
  <study_first_submitted_qc>July 8, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">July 9, 2020</study_first_posted>
  <last_update_submitted>December 11, 2020</last_update_submitted>
  <last_update_submitted_qc>December 11, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 14, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

